Ultra Market Research | North America EGFR and HER2 targeted NSCLC
North America EGFR and HER2 targeted NSCLC
Report ID : 867
Category : Healthcare-Companies,North-America
No Of Pages : 145
Published on: November 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction
The North America EGFR & HER2 targeted NSCLC market is rapidly evolving, driven by advancements in oncology therapeutics. Non-Small Cell Lung Cancer (NSCLC) represents the majority of lung cancer cases, with mutations in the EGFR (Epidermal Growth Factor Receptor) and HER2 (Human Epidermal Growth Factor Receptor 2) pathways playing a critical role in tumor growth and survival. EGFR & HER2 targeted therapies offer precision medicine approaches by inhibiting these receptors, resulting in improved patient outcomes. The growing adoption of next-generation sequencing (NGS) has facilitated precise identification of mutations, boosting the development of targeted treatments. Recent trends highlight increasing approvals for innovative EGFR & HER2 inhibitors and combination therapies in North America, positioning this market for significant growth.
Segmentation
Therapeutics Targeted Therapy
EGFR Tyrosine Kinase Inhibitors (TKIs)
First-Generation TKIs
Second-Generation TKIs
Third-Generation TKIs
Others
HER2 Inhibitors
Monoclonal Antibodies
Antibody-Drug Conjugates
Others Immunotherapy
Immune Checkpoint Inhibitors
T-Cell Engagers
Others
Diagnostics Biopsy-Based Tests
Tissue Biopsy
Fluorescence In Situ Hybridization (FISH)
Immunohistochemistry (IHC)
Others
Liquid Biopsy
Circulating Tumor DNA (ctDNA)
Exosome Analysis
Others Molecular Diagnostic Tools
Polymerase Chain Reaction (PCR)
Next-Generation Sequencing (NGS)
Others
Market Players
AstraZeneca (UK)
Roche (Switzerland)
Pfizer (USA)
Novartis (Switzerland)
Amgen (USA)
Merck & Co. (USA)
Eli Lilly and Company (USA)
Daiichi Sankyo (Japan)
Takeda Pharmaceutical Company (Japan)
Johnson & Johnson (USA)
Boehringer Ingelheim (Germany)
Sanofi (France)
Blueprint Medicines (USA)
Genmab (Denmark)
Regeneron Pharmaceuticals (USA)
Drivers
The North America EGFR & HER2 targeted NSCLC market is driven by the rising prevalence of NSCLC, which accounts for about 85% of lung cancer cases. Enhanced awareness and early diagnosis have accelerated the demand for advanced therapies. Advancements in molecular diagnostics like NGS have enabled precise identification of EGFR and HER2 mutations, fostering personalized treatment. Favorable regulatory pathways in North America, including fast-track designations by the FDA, have streamlined the approval of innovative therapies. Additionally, the increasing preference for targeted therapies over traditional chemotherapy is reshaping treatment protocols. Investments in research and development by major pharmaceutical players further drive market growth.
Restraints
Despite promising advancements, the market faces several challenges. High treatment costs for EGFR & HER2 targeted therapies pose a significant barrier to their widespread adoption. Limited access to advanced diagnostics in certain regions within North America restricts early detection of EGFR and HER2 mutations. Resistance mechanisms developed by tumors against first- and second-generation inhibitors remain a clinical hurdle. Additionally, adverse effects associated with these therapies, including severe gastrointestinal and skin toxicities, can limit their prolonged use. Competition from alternative therapeutic approaches, such as immunotherapies, adds to market pressures.
Opportunities
The North America EGFR & HER2 targeted NSCLC market offers vast growth opportunities due to ongoing research into next-generation inhibitors that overcome resistance. Emerging technologies, such as AI-driven diagnostic platforms, enable faster and more accurate detection of actionable mutations. Collaborative partnerships between pharmaceutical companies and academic institutions are fostering innovative drug development. Expansion of healthcare infrastructure in underserved regions within North America promises broader access to advanced treatments. Biosimilar development for existing inhibitors offers cost-effective options, further driving market penetration.
Trends
The market is witnessing a shift towards combination therapies, integrating EGFR inhibitors with immunotherapy or chemotherapy to enhance treatment efficacy. The emergence of fourth-generation EGFR inhibitors addressing resistance mechanisms is a notable trend. Real-world evidence (RWE) studies are increasingly shaping clinical decision-making, optimizing therapy selection. Telemedicine adoption during clinical trials has streamlined patient enrollment and monitoring. The focus on biomarker-driven clinical trials ensures precise patient selection, improving success rates. Additionally, patient-centric drug development, prioritizing quality of life metrics, is gaining momentum in North America.
Approved Products
Tagrisso (AstraZeneca)
Lumakras (Amgen)
Enhertu (Daiichi Sankyo/AstraZeneca)
Tecentriq (Roche)
Portrazza (Eli Lilly and Company)
Pipeline/Registered/Pre-Registered Products
BLU-945 (Blueprint Medicines)
Amivantamab (Johnson & Johnson)
HER3-DXd (Daiichi Sankyo)
Lazertinib (Yuhan/Johnson & Johnson)
BI-1701963 (Boehringer Ingelheim)
Key Target Audience
Oncology Clinics and Hospitals
Pharmaceutical and Biotechnology Companies
Research and Academic Institutions
Diagnostic Laboratories
Contract Research Organizations (CROs)
Government and Regulatory Authorities
FAQs
EGFR and HER2 are proteins involved in cell signaling pathways. Mutations in these genes drive tumor growth in certain NSCLC patients, making them targets for precision therapies.
North America’s advanced healthcare infrastructure, high incidence of NSCLC, and supportive regulatory environment contribute to its market prominence.
NGS helps identify EGFR and HER2 mutations, enabling personalized treatment and driving demand for advanced diagnostics and therapies.
High costs, tumor resistance, and treatment-related adverse effects are significant challenges.
Combination therapies improve efficacy by targeting multiple pathways, addressing resistance, and expanding treatment options for NSCLC patients.
Introduction 1.1 Definition of EGFR & HER2 Targeted NSCLC 1.2 Applications in the Treatment of NSCLC 1.3 Recent Trends in the North America Market
Table 5: Leading Companies in the North America EGFR & HER2 Targeted NSCLC Market
Table 6: Market Drivers and Their Impact on Market Growth
Table 7: Key Restraints Impacting Market Adoption
Table 8: Emerging Opportunities for Market Expansion
Table 9: Approved EGFR & HER2 Targeted Products in North America
Table 10: Pipeline Products Under Development
Table 11: Key Target Audience for Market Research Reports
Table 12: FAQs - Insights into the North America Market
Research Methodology
The process of market research at Ultra Market Research is an iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings Internal and external proprietary databases, relevant patent and regulatory databases National government documents, statistical databases and market reports News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process Middle Circle Represents – Source of Information Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc. Helps in validating and strengthening the secondary research findings Further develops the analysis team’s expertise and market understanding Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers Purchasing managers, technical personnel, distributors and resellers Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment Macro-economic indicators: GDP, etc. Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities. Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Global market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps:
2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach. 2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of North America EGFR & HER2 Targeted NSCLC Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Globally. Regional average price has been considered while breaking down this market by application in each region.
This report provides market size of North America EGFR & HER2 Targeted NSCLC Market for the past year and forecasts for the next six years. North America EGFR & HER2 Targeted NSCLC Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different North America EGFR & HER2 Targeted NSCLC Market categories. Market size and forecasts for each major application is provided in the context of Global market. The numbers provided in this report are derived on the basis of demand for Global Skincare Treatment from different application industries in different regions.
